Expert Review of Anticancer Therapy最新文献_第6页

Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer. sacituzumab govitecan治疗晚期/转移性非小细胞肺癌的评估

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-05 DOI: 10.1080/14737140.2025.2515989

Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas

{"title":"Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer.","authors":"Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas","doi":"10.1080/14737140.2025.2515989","DOIUrl":"10.1080/14737140.2025.2515989","url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).Areas covered: Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.Expert opinion: Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"845-852"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ablative radiotherapy for polymetastatic disease: a new kid on the block. 消融放疗治疗多转移性疾病：一个新的孩子在街区。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 DOI: 10.1080/14737140.2025.2542191

Federico Camilli, Andrea Lancia, Sheetal R Kashid, Jatin Bhatia, Ajay Gubbi Vijayakumar, Asha Latha Devalla, Lorenzo Falcinelli, Simonetta Saldi, Cynthia Aristei, Beatrice Detti, Gianluca Ingrosso

{"title":"Ablative radiotherapy for polymetastatic disease: a new kid on the block.","authors":"Federico Camilli, Andrea Lancia, Sheetal R Kashid, Jatin Bhatia, Ajay Gubbi Vijayakumar, Asha Latha Devalla, Lorenzo Falcinelli, Simonetta Saldi, Cynthia Aristei, Beatrice Detti, Gianluca Ingrosso","doi":"10.1080/14737140.2025.2542191","DOIUrl":"https://doi.org/10.1080/14737140.2025.2542191","url":null,"abstract":"Introduction: In polymetastatic cancer, radiotherapy (RT) serves as a palliative and symptom-directed approach. Based on modern RT, ablative irradiation has acquired a central role as a metastasis-directed therapy (MDT). MDT is under investigation as a treatment option in patients with widespread metastatic disease.Areas covered: We aimed to describe the emerging field of radiotherapy-based MDT in polymetastatic disease.Expert opinion: New innovative approaches in radiation oncology allow for the precise and safe delivery of ablative doses to multiple disease sites throughout the body in the same treatment session and the tracking of tumors in real time without interruptions during systemic therapy. This treatment strategy could work synergistically with systemic therapy in two ways: [a] ablating high-risk or symptomatic metastases in polymetastatic patients may prevent further disease spread and reduce the overall tumor burden, even while systemic therapy continues to manage micrometastatic disease elsewhere; [b] delivering high doses of radiation to the tumor site leads to microenvironment modifications, inducing immunogenic cell death, releasing tumor antigens, and enhancing immune surveillance and systemic therapy efficacy. Several clinical trials are ongoing to improve tailored treatment strategies in the polymetastatic setting, which is one of the goals of precision medicine.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now? CAR-T细胞治疗t淋巴母细胞白血病/淋巴瘤：目前进展如何？

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-08 DOI: 10.1080/14737140.2025.2515981

Pedro Chorão, Pilar Lloret, Pau Montesinos, Manuel Guerreiro

{"title":"CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now?","authors":"Pedro Chorão, Pilar Lloret, Pau Montesinos, Manuel Guerreiro","doi":"10.1080/14737140.2025.2515981","DOIUrl":"10.1080/14737140.2025.2515981","url":null,"abstract":"Introduction: CAR-T therapies for relapsed or refractory (r/r) T-cell lymphoblastic leukemia/lymphoma (T-LL/L) faces challenges, with most clinical studies conducted in small, dispersed cohorts and often reviewed alongside preclinical studies. This review focuses exclusively on clinical studies, evaluating CAR constructs, safety and efficacy.Methods: A systematic review was conducted of databases, clinical trial registries, and abstracts from conferences (June 2014 to June 2024). Preclinical studies and studies lacking clinical details were excluded. Data on patient demographics, CAR-T characteristics, response rates, survival, and adverse events were analyzed.Results: Eleven CAR-T constructs targeting CD7 and two targeting CD5 were identified. Complete remission (CR/CRi) rates ranged from 55% to 100%, exceeding 80% in most studies. Relapse, often in extramedullary sites, ranged from 7% to 66%. Cytokine release syndrome and neurotoxicity were generally manageable. GVHD incidence varied (none to 60%), primarily in allogeneic CAR-T recipients. Infections contributed to 6-38% of treatment-related mortality.Conclusions: CAR-T therapy achieves high response rates in r/r T-LL/L and may serve as a bridge to allogeneic transplantation. However, the short follow-up and the duration of responses remain concerns, and challenges endure, including GVHD, immune recovery and infection control. Standardized reporting is crucial to optimize therapy outcomes and safety in future trials.Registration: PROSPERO (CRD420251024662).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"939-948"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologically synthesized metallic nanocarriers for efficient therapy of breast cancer. 生物合成金属纳米载体有效治疗乳腺癌。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI: 10.1080/14737140.2025.2515977

Saili Jagdale, Rajkumar Samanta, Mahavir Narwade, Niladri Haldar, Rajesh Jadon, Virendra Gajbhiye, Kavita R Gajbhiye

{"title":"Biologically synthesized metallic nanocarriers for efficient therapy of breast cancer.","authors":"Saili Jagdale, Rajkumar Samanta, Mahavir Narwade, Niladri Haldar, Rajesh Jadon, Virendra Gajbhiye, Kavita R Gajbhiye","doi":"10.1080/14737140.2025.2515977","DOIUrl":"10.1080/14737140.2025.2515977","url":null,"abstract":"Introduction: Breast cancer is one of the most common cancers in women and has a high mortality rate. Current treatment methods, including radiation, chemotherapy, and surgery, have limitations such as surrounding tissue damage and nonspecific toxicity, reducing their effectiveness. As a result, new therapeutic platforms are needed to enhance breast cancer treatment.Areas covered: Nanoparticles, particularly metallic nanoparticles, have shown significant potential in overcoming the limitations of conventional treatments. These nanoparticles offer advantages such as high loading capacity, biocompatibility, adjustable size, and surface modification flexibility, making them ideal for drug delivery. This review focuses on the synthesis of metallic nanoparticles, emphasizing chemical and green synthesis methods. The green synthesis method has gained attention due to its eco-friendliness, biological safety, and cost-effectiveness. Research advancements in biosynthesized metallic nanoparticles for breast cancer therapy are discussed.Expert opinion: The use of bio-synthesized magnetic nanoparticles in the treatment of breast cancer shows promise for both cytotoxicity and targeted medication delivery. By increasing anti-tumor immune responses, their optical and magnetic qualities improve immunotherapy's efficacy. Furthermore, It have the potential to provide potent anticancer treatments and stimulate multidisciplinary research to address current obstacles in the treatment of breast cancer, opening up new therapeutic development pathways.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"865-882"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma. 皮下泛膜炎样t细胞淋巴瘤患者的临床特征和预后。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-07 DOI: 10.1080/14737140.2025.2517280

Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu

{"title":"Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma.","authors":"Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu","doi":"10.1080/14737140.2025.2517280","DOIUrl":"10.1080/14737140.2025.2517280","url":null,"abstract":"Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and highly heterogeneous cytotoxic T-cell lymphoma with unknown epidemiology, clinical features, and prognosis.Methods: We retrospectively analyzed data on patients with SPTCL from the Surveillance, Epidemiology, and End Results database (2000-2021). Joinpoint plots of incidence were created. Independent prognostic factors for overall survival (OS) and lymphoma-specific survival (LSS) were analyzed using univariate Cox regression analysis. Kaplan - Meier analyses were performed to assess survival.Results: Among 258 included patients, we observed an increase in the overall incidence of SPTCL, particularly among individuals aged ≥ 50. The age at SPTCL onset exhibited a unimodal distribution, with peak incidence in the 60-69-year age group. Multivariate Cox regression analysis indicated that diagnoses made between 2000 and 2006, as well as age ≥ 50, were associated with reduced OS and LSS. We describe a case of primary maxillofacial SPTCL in a pediatric patient at our center.Conclusions: SPTCL has unique clinical and pathological characteristics and tends to occur in younger patients. Early identification and active treatment are beneficial for improving prognosis and survival.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"973-981"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal symptoms in the journey of pancreatic cancer patients. 胰腺癌患者治疗过程中的胃肠道症状

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-26 DOI: 10.1080/14737140.2025.2517888

Ruggero Ponz de Leon Pisani, Gabriele Altieri, Rosa Claudia Stasio, Pilar Lazzano, Michele Reni, Massimo Falconi, Giuseppe Vanella, Paolo Giorgio Arcidiacono, Gabriele Capurso

{"title":"Gastrointestinal symptoms in the journey of pancreatic cancer patients.","authors":"Ruggero Ponz de Leon Pisani, Gabriele Altieri, Rosa Claudia Stasio, Pilar Lazzano, Michele Reni, Massimo Falconi, Giuseppe Vanella, Paolo Giorgio Arcidiacono, Gabriele Capurso","doi":"10.1080/14737140.2025.2517888","DOIUrl":"10.1080/14737140.2025.2517888","url":null,"abstract":"Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy frequently arising with nonspecific and overlooked gastrointestinal symptoms. Gastroenterologists are typically the first specialists to encounter these patients, positioning them to play a pivotal role not only in early diagnosis, but also in the ongoing management of the disease's complex symptom burden.Areas covered: This review explored gastrointestinal symptoms in patients with PDAC (ranging from pain and diarrhea to anorexia, jaundice, and nausea) and outlined both tumor- and treatment-related causes. A literature review based on non-systematic PubMed search updated to April 2025 was conducted to summarize current diagnostic strategies, medical, endoscopic therapies, and multidisciplinary management approaches. In addition, we present original data from a single-center cohort, suggesting that the involvement of gastroenterologists leads to more comprehensive management of gastrointestinal symptom control and supportive care.Expert opinion: Collaboration among specialists is essential for optimizing patient outcomes in the multidisciplinary management of PDAC. Gastroenterologists' 'stewardship' significantly contributes to prompt diagnosis, symptom control, quality of life preservation, and prognosis. Future priorities should focus on strengthening integration within care pathways, fostering interdisciplinary coordination, and implementing shared clinical tools to enhance comprehensive patient care. A well-structured team-based approach is key to advancing holistic PDAC management.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"883-900"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes. 免疫检查点抑制剂因免疫相关不良事件停药后恢复：基于nomogram危险因素和结果分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-10 DOI: 10.1080/14737140.2025.2517274

Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Burçak Karaca

{"title":"Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes.","authors":"Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Burçak Karaca","doi":"10.1080/14737140.2025.2517274","DOIUrl":"10.1080/14737140.2025.2517274","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) elicit strong antitumour responses but may cause immune-related adverse events (irAEs) requiring treatment interruption. Resuming ICIs after irAEs remains a clinical challenge.Methods: This single-center retrospective study included 97 patients with solid tumors treated with anti-PD-1 ± anti-CTLA-4 agents between January 2016 and September 2024. All patients developed irAEs that led to treatment interruption and subsequently resumed the same ICI regimen. Predictors of irAE recurrence were evaluated using LASSO regression followed by backward stepwise selection.Results: The patient cohort had a median age of 60 years. 63.9% had received anti-PD-1 monotherapy and 36.1% had received combination therapy. Common first irAEs included colitis (37.1%) and hepatitis (24.7%), with 40.2% being grade ≥ 3. Upon resumption, 46.4% experienced recurrent irAEs. Overall survival did not differ significantly between patients with and without recurrence (84.3 vs. 74.6 months, p = 0.866). Younger age, high-grade irAE, colitis, elevated monocytes, and need for nonsteroidal immunosuppressants were independently associated with recurrence. A nomogram constructed using these factors demonstrated good discriminative ability (AUC = 0.818).Conclusion: Resuming ICI therapy after an irAE is generally feasible, although nearly 50% of patients experience recurrent toxicity. The developed nomogram may support risk-based clinical decisions.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"983-991"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors. 结直肠癌转移中主要信号通路的参与及其抑制剂的治疗应用。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-10 DOI: 10.1080/14737140.2025.2519860

Mehran Molavand, Majid Montazer, Somayyeh Ghareghomi, Bahman Yousefi, Maryam Majidinia

{"title":"The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors.","authors":"Mehran Molavand, Majid Montazer, Somayyeh Ghareghomi, Bahman Yousefi, Maryam Majidinia","doi":"10.1080/14737140.2025.2519860","DOIUrl":"10.1080/14737140.2025.2519860","url":null,"abstract":"Introduction: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality, with metastasis being a key determinant of poor prognosis. Understanding the molecular mechanisms governing CRC metastasis is crucial for developing targeted therapeutic strategies. This review focuses on the involvement of major signaling pathways in CRC metastasis and their potential as therapeutic targets.Areas covered: This review discusses the role of key signaling pathways, including PI3K/Akt, MAPK/ERK, Notch, Wnt/β-catenin, Hippo, and Hedgehog in CRC metastasis. We conducted a literature review using databases such as PubMed and Web of Science to identify recent studies on the molecular mechanisms of metastasis and the efficacy of pathway-targeted therapies.Expert opinion: The complexity of CRC metastasis underscores the need for multi-targeted therapeutic approaches. While significant advances have been made in pathway-specific inhibitors, clinical translation remains challenging. Further research is needed to refine biomarker-driven treatments and develop novel combination therapies to improve patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"915-938"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation challenges of single-instillation intravesical chemotherapy following transurethral resection of bladder tumor. 经尿道膀胱肿瘤切除术后单次膀胱内灌注化疗的实施挑战。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-07-23 DOI: 10.1080/14737140.2025.2537793

Kamil Malshy, Alexis Steinmetz, Edward M Messing

{"title":"Implementation challenges of single-instillation intravesical chemotherapy following transurethral resection of bladder tumor.","authors":"Kamil Malshy, Alexis Steinmetz, Edward M Messing","doi":"10.1080/14737140.2025.2537793","DOIUrl":"10.1080/14737140.2025.2537793","url":null,"abstract":"Introduction: Despite strong evidence supporting its effectiveness, single, immediate instillation of intravesical chemotherapy (SI-IVC) following transurethral resection of bladder tumor (TURBT) remains vastly underutilized in managing low- and intermediate-risk non - non-muscle-invasive bladder cancer (NMIBC). This review addresses the gap between evidence and practice in adopting this cost-effective, recurrence-reducing intervention and offers potential solutions through an implementation science approach.Areas covered: We examined the clinical benefits of SI-IVC based on landmark trials and meta-analyses across various agents, including mitomycin and gemcitabine. A targeted literature review was conducted using PubMed and major urology guidelines to identify studies assessing efficacy, utilization rates, and barriers to implementation. Particular focus is given to logistical and systems-based challenges limiting real-world application, including issues with drug availability, perioperative workflow, and post-resection coordination. We also discuss strategies informed by an implementation science framework, including planning and system engagement, executing interventions, and evaluating their impact within hospital systems.Expert opinion: Incorporating SI-IVC into routine practice requires pragmatic, system-level changes that address logistical barriers rather than clinical hesitancy. With institutional support and streamlined protocols, SI-IVC can be more consistently delivered, however, local adaptation and fine-tuning remain essential, as healthcare systems and available personnel vary across institutions.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer. 新发小体积转移性激素敏感前列腺癌的当前诊断和治疗选择。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-21 DOI: 10.1080/14737140.2025.2509760

Gianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, Carlotta Becherini, Marta Bottero, Niccolò Bertini, Tommaso Cai, Saverio Caini, Claudia Caserta, Chiara Doccioli, Eleonora Festa, Giulio Francolini, Irene Giacomelli, Federico Paolieri, Daniele Scartoni, Antonio Rosario Pisani, Rita Bellavita, Lorenzo Livi, Cynthia Aristei, Beatrice Detti

{"title":"Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer.","authors":"Gianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, Carlotta Becherini, Marta Bottero, Niccolò Bertini, Tommaso Cai, Saverio Caini, Claudia Caserta, Chiara Doccioli, Eleonora Festa, Giulio Francolini, Irene Giacomelli, Federico Paolieri, Daniele Scartoni, Antonio Rosario Pisani, Rita Bellavita, Lorenzo Livi, Cynthia Aristei, Beatrice Detti","doi":"10.1080/14737140.2025.2509760","DOIUrl":"10.1080/14737140.2025.2509760","url":null,"abstract":"Introduction: de novo low-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients are characterized by a limited number of metastases at diagnosis. Intensifying the current diagnostic and therapeutic approach including multimodality therapy seems to be key in the clinical management of such patients.Areas covered: We comprehensively review the current staging and treatment options for de novo low-volume mHSPC.Expert opinion: PSMA-PET should be used in staging high-risk prostate cancer to detect metastatic disease and better stratify patients for individualized treatment. In the era of Androgen Receptor Pathway Inhibitors (ARPIs), Androgen Deprivation Therapy (ADT) alone should be considered an undertreatment for the majority of the patients. Based on current data in the literature, the most effective therapeutic strategy seems to be the combination of intensified systemic treatment (including ADT + ARPI) and radiotherapy for the primary tumor. The role of cytoreductive radical prostatectomy is currently being investigated as well as metastasis-directed therapy to metastatic sites.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"741-754"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0